Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
- LEAP-002 Investigators
- Icahn School of Medicine at Mount Sinai
- Hospital Clínic de Barcelona
- Kindai University
- Hôpital de la Croix-Rousse
- Royal Free London NHS Foundation Trust
- University College London
- Nanjing Tianyinshan Hospital
- National Cancer Center Japan
- Central South University
- Centre Georges-François Leclerc
- University of Ulsan
- Fudan University
- University of Pisa
- Nicolaus Copernicus Provincial Hospital
- Samsung Medical Center, Sungkyunkwan university
- Seoul National University
- Russian Academy of Medical Sciences - N.N. Blokhin Russian Cancer Research Center
- Toranomon Hospital
- National Taiwan University
- Johannes Gutenberg University Mainz
- Kanazawa University
- Merck
- Eisai Co., Ltd.
- University of California at Los Angeles
- Liverpool Hospital
Research output: Contribution to journal › Article › peer-review
388
Citations
(Scopus)